Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/82627
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMohamed, A. Allam-
dc.contributor.authorThomsen, Andreas-
dc.contributor.authorFollo, Marie-
dc.contributor.authorZamboglou, Costantinos-
dc.contributor.authorBronsert, Peter-
dc.contributor.authorMostafa, Hanan-
dc.contributor.authorAmen, Aber-
dc.contributor.authorMekawy, Mohamed-
dc.contributor.authorGrosu, Anca-Ligia-
dc.contributor.authorBrunner, Thomas B.-
dc.date.accessioned2022-04-12T08:40:26Z-
dc.date.available2022-04-12T08:40:26Z-
dc.date.issued2021-
dc.date.submitted2021-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/84582-
dc.identifier.urihttp://dx.doi.org/10.25673/82627-
dc.description.abstractIntroduction Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase protein frequently overexpressed in cancer and has been linked to an increase in the stem cell population of tumors, resistance to therapy, and metastatic spread. Pharmacological FAK inhibition in pancreatic cancer has received increased attention over the last few years, either alone or in combination with other therapeutics including chemotherapy and immunotherapy. However, its prognostic value and its role in radioresistance of pancreatic ducal adenocarcinoma (PDAC) is unknown. Methods and materials Using the TCGA and GTEx databases, we investigated the genetic alterations and mRNA expression levels of PTK2 (the encoding-gene for FAK) in normal pancreatic tissue and pancreatic cancer and its impact on patient survival. Furthermore, we evaluated the expression of FAK and its tyrosine domain Ty-397 in three pancreatic cancer cell lines. We went further and evaluated the role of a commercial FAK tyrosine kinase inhibitor VS-4718 on the viability and radiosensitization of the pancreatic cell lines as well as its effect on the extracellular matrix (ECM) production from the pancreatic stellate cells. Furthermore, we tested the effect of combining radiation with VS-4718 in a three-dimensional (3D) multicellular pancreatic tumor spheroid model. Results A database analysis revealed a relevant increase in genetic alterations and mRNA expression of the PTK2 in PDAC, which were associated with lower progression-free survival. In vitro, there was only variation in the basal phosphorylation level of FAK in cell lines. VS-4718 radiosensitized pancreatic cell lines only in the presence of ECM-producing pancreatic stellate cells and markedly reduced the ECM production in the stromal cells. Finally, using a 3D multicellular tumor model, the combination of VS-4718 and radiotherapy significantly reduced the growth of tumor aggregates. Conclusion Pharmacological inhibition of FAK in pancreatic cancer could be a novel therapeutic strategy as our results show a radiosensitization effect of VS-4718 in vitro in a multicellular 2D- and in a 3D-model of pancreatic cancer.eng
dc.description.sponsorshipProjekt DEAL 2020-
dc.language.isoeng-
dc.relation.ispartofhttp://link.springer.com/journal/66-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectPancreatic ductal adenocarcinomaeng
dc.subjectFocal adhesion kinaseeng
dc.subjectRadiosensitizationeng
dc.subjectPancreatic stellate celleng
dc.subjectMicroenvironmenteng
dc.subjectStromaeng
dc.subject.ddc610.72-
dc.titleFAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitroeng
dc.typeArticle-
dc.identifier.urnurn:nbn:de:gbv:ma9:1-1981185920-845828-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleStrahlentherapie und Onkologie-
local.bibliographicCitation.volume197-
local.bibliographicCitation.issue1-
local.bibliographicCitation.pagestart27-
local.bibliographicCitation.pageend38-
local.bibliographicCitation.publishernameSpringer Medizin-
local.bibliographicCitation.publisherplaceBerlin-
local.bibliographicCitation.doi10.1007/s00066-020-01666-0-
local.openaccesstrue-
dc.identifier.ppn1772735019-
local.bibliographicCitation.year2021-
cbs.sru.importDate2022-04-12T08:34:39Z-
local.bibliographicCitationEnthalten in Strahlentherapie und Onkologie - Berlin : Springer Medizin, 1997-
local.accessrights.dnbfree-
Appears in Collections:Medizinische Fakultät (OA)

Files in This Item:
File Description SizeFormat 
Mohamed et al._FAK inhibition_2021.pdfZweitveröffentlichung3.52 MBAdobe PDFThumbnail
View/Open